Trastuzumab deruxtecan companion diagnostic - Guardant Health
Alternative Names: trastuzumab deruxtecan Guardant360® CDx companion diagnosticLatest Information Update: 15 Jan 2024
At a glance
- Originator Guardant Health
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Non-small cell lung cancer
Most Recent Events
- 05 Sep 2023 Registered for Non-small cell lung cancer (Diagnosis, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Recurrent) in Japan (unspecified route)
- 12 Aug 2022 Registered for Non-small cell lung cancer (Diagnosis, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Recurrent) in USA (unspecified route) (Guardant Health pipeline, October 2023)